Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) shares shot up 33.3% during trading on Wednesday . The company traded as high as C$0.02 and last traded at C$0.02. 388,000 shares changed hands during trading, an increase of 186% from the average session volume of 135,847 shares. The stock had previously closed at C$0.02.
Aequus Pharmaceuticals Price Performance
The company has a debt-to-equity ratio of 138.88, a current ratio of 0.12 and a quick ratio of 0.46. The stock has a market capitalization of C$1.99 million, a price-to-earnings ratio of -0.75 and a beta of 0.37. The stock’s 50 day simple moving average is C$0.02 and its 200-day simple moving average is C$0.03.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Further Reading
- Five stocks we like better than Aequus Pharmaceuticals
- 3 Monster Growth Stocks to Buy Now
- Here are the Pros and Cons of Using Options Call Debit Spreads
- How to Effectively Use the MarketBeat Ratings Screener
- Carmax Returns to the Bargain Basement: Buy the Dip?
- How to Calculate Inflation Rate
- Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
